Ondansetron for the Management of Atrial Fibrillation — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Ondansetron for the Management of Atrial Fibrillation — Stella

Recruiting

Back to Atrial Fibrillation trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(3 sites)

United States

Indiana Clinical Research Center, Indianapolis, Indiana

Indiana University Health Methodist Hospital, Indianapolis, Indiana

Purdue University, Indianapolis, Indiana

Key details

Phase

Post-approval study

Sponsor

Indiana University

Collaborators

American Heart Association, Purdue University

Enrollment target

~80 participants

Started

April 2025

Primary completion

December 2027

Age range

18 Years – 100 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov